Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum toxin A with or without best practice therapy for post-stroke or acquired brain injury spasticity
ACTRN12612000091808Phase 4Completed
- Sponsor
- Associate Professor Natasha Lannin
- Start
- Sep 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of botulinum toxin type A in Muscle spasm, stroke and acquired brain injury (ABI) (3 arms), sponsored by Associate Professor Natasha Lannin. Primary endpoint: Goal attainment at 90 days. Started Sep 2010; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
Muscle spasmstrokeacquired brain injury (ABI)
Beyond the preview
Go deeper on ACTRN12612000091808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000091808.